HRTX
HERON THERAPEUTICS, INC. /DE/
NASDAQ · Healthcare · Biotechnology · US
$0.37
+2.35%Year over year
Reported trailing growth
- Revenue
- +1.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +58.9%
- Operating cash flow
- +58.8%
Forward estimates
Based on analyst estimates
- Revenue
- -74.6%
- EBITDA
- +82.5%
- EPS
- +84.0%
Three-year CAGR
- Revenue
- +12.9%
- EBITDA
- —
- EBIT
- +78.0%
- Net income
- -48.7%
- EPS
- -34.7%
- Free cash flow
- -15.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026